Cardiovascular Systems

Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardiovascular Systems, Inc. (CSI) is devoted to developing and commercializing innovative solutions for treating peripheral and coronary vascular disease. Their primary focus is helping physicians conquer even the most difficult disease states, including calcium, given the complications. Cardiovascular Systems develop solutions for the treatment of peripheral and coronary artery disease, to help physicians conquer calcium, one of the largest challenges when treating PAD and CAD.

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Cardiovascular Systems (CSII) Q1 Earnings Expected to Decline

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2021 first-quarter conference call on Wednesday, November 4, 2020, at 3:30 p.m. CT (4:30 p.m. ET). CSI management will discuss results for its fiscal first quarter ended September 30, 2020, and its financial outlook. CSI will issue a post-market earnings release prior to the call on November 4, 2020. To access the live webcast, go to the events section of CSI's investor re

Cardiovascular Systems, Inc. to Webcast Fiscal 2021 First-Quarter Earnings Conference Call Wednesday, November 4

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a large retrospective observational study of coronary orbital atherectomy were released at TCT Connect 2020. The presentation, authored by Nirat Beohar, MD, Professor of Medicine and Vice Chief, Columbia University Divisi

Large Study Demonstrates Exceptional Safety and High Procedural Success With Cardiovascular Systems’ Diamondback 360® Coronary Orbital Atherectomy System (OAS)

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a large retrospective observational study of coronary orbital atherectomy will be released at TCT Connect 2020. Severe calcification of coronary lesions represents a major challenge when aiming for optimal stent delivery,

Cardiovascular Systems Announces Presentation of Data From Large Coronary Orbital Atherectomy Study at the TCT Connect 2020 Conference

Cardiovascular Systems' (CSII) encouraging REACH PVI study outcome and launch of a physician finder are positives.

Cardiovascular Systems Rides on Launches Amid Coronavirus Woes

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?

Cardiovascular Systems (CSII) Up 9.7% Since Last Earnings Report: Can It Continue?

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC.

Cardiovascular Systems, Inc. Announces Kelvin Womack Joins Board of Directors

Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q4 earnings as patients avoid hospitals.

Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected (Revised)

Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q2 earnings as patients avoid hospitals.

Cardiovascular Systems (CSII) Misses Q4 Earnings Estimates

Cardiovascular Systems' (CSII) CEO Scott Ward on Q4 2020 Results - Earnings Call Transcript

Cardiovascular Systems, Inc. Reports Fiscal 2020 Fourth-Quarter Financial Results

Cardiovascular Systems (NASDAQ: CSII) releases its next round of earnings this Tuesday, August 04.

Earnings Outlook for Cardiovascular Systems

Earnings Preview: Cardiovascular Systems (CSII) Q4 Earnings Expected to Decline

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS PRESENTS REACH PVI STUDY AT THE NEW CARDIOVASCULAR  HORIZONS CONFERENCE

Cardiovascular Systems Presents REACH PVI Study at the New Cardiovascular Horizons Conference

The market is reacting to the company's decision to initiate a public offering of common stock.

Why Cardiovascular Systems Is Down Today

Cardiovascular Systems (CSII) witnesses a significant decline in procedure volumes in Q3 for patients treated with orbital atherectomy devices.

Cardiovascular Systems (CSII) Reports Q3 Loss, Lower Margin

Cardiovascular Systems' (CSII) CEO Scott Ward on Q3 2020 Results - Earnings Call Transcript

Why Is Cardiovascular Systems (CSII) Down 10.8% Since Last Earnings Report?

Cardiovascular Systems (CSII) continues to register solid top-line growth on strength in the domestic atherectomy businesses.

Cardiovascular Systems Grows on Domestic Sales Amid Margin Woe

Harmonic

IAC/InterActiveCorp

Mimecast

Myriad Genetics

Figuring out bloated toxic stocks on a consistent basis and discarding them at the right time is the key to successful investing.

Steer Clear Of These 5 Toxic Stocks Before It's Too Late

We are upbeat about Cardiovascular Systems' (CSII) year-over-year uptick in global Coronary and peripheral device revenues during Q2.

Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q2

Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q2 2020 Results - Earnings Call Transcript

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -233.33% and 0.65%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Cardiovascular Systems (CSII) Reports Q2 Loss, Tops Revenue Estimates

Cardiovascular Systems (CSII) is optimistic about maintaining its growth momentum on several recent developments.

Cardiovascular Systems (CSII) Stock Hits New 52-Week High

This is a major achievement for Cardiovascular Systems (CSII) toward strengthening its portfolio for the treatment of CLI.

News for Cardiovascular Systems Stock (CSII)